

Jos Caetano Villasboas-Bisneto

List of Publications by Citations

Source:

<https://exaly.com/author-pdf/3787580/jose-caetano-villasboas-bisneto-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

327
citations

9
h-index

17
g-index

95
ext. papers

526
ext. citations

3.4
avg, IF

3.39
L-index

#	Paper	IF	Citations
85	Expression of LAG-3 defines exhaustion of intratumoral PD-1 T cells and correlates with poor outcome in follicular lymphoma. <i>Oncotarget</i> , 2017 , 8, 61425-61439	3.3	83
84	ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. <i>Onc Immunology</i> , 2020 , 9, 1744980	7.2	40
83	Mass Cytometry Analysis Reveals that Specific Intratumoral CD4 T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma. <i>Cell Reports</i> , 2019 , 26, 2178-2193.e3	10.6	37
82	Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies. <i>Blood Cancer Journal</i> , 2019 , 9, 72	7	21
81	SIRP α expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma. <i>Blood Cancer Journal</i> , 2019 , 9, 84	7	16
80	Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2016 , 22, 17-22	2.2	13
79	Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 5-12	3.5	12
78	Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , 2019 , 9, 65	7	12
77	Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. <i>Blood Advances</i> , 2020 , 4, 5425-5430	7.8	10
76	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. <i>American Journal of Hematology</i> , 2019 , 94, 658-666	7.1	9
75	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. <i>Blood</i> , 2019 , 134, 121-121	2.2	7
74	Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis. <i>Leukemia Research</i> , 2019 , 81, 1-9	2.7	5
73	Does Bridging Radiation Therapy Affect the Pattern of Failure After CAR T-cell Therapy in Non-Hodgkin Lymphoma?. <i>Radiotherapy and Oncology</i> , 2021 ,	5.3	5
72	Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. <i>Blood Cancer Journal</i> , 2021 , 11, 130	7	5
71	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma. <i>Blood</i> , 2019 , 134, 4106-4106	2.2	4
70	Recent advances in the management of Hodgkin lymphoma. <i>F1000Research</i> , 2016 , 5,	3.6	4
69	Targeted Approaches Applied to Uncommon Diseases: A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib. <i>Case Reports in Oncology</i> , 2017 , 10, 726-731	1	3

68	A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2019 , 134, 4306-4306	2.2	3
67	The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672). <i>Blood</i> , 2019 , 134, 1591-1591	2.2	3
66	Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. <i>International Journal of Cancer</i> , 2021 , 149, 378-386	7.5	3
65	Lines of therapy before autologous stem cell transplant and CAR-T affect outcomes in aggressive Non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2021 , 96, E386-E389	7.1	3
64	The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy. <i>American Journal of Hematology</i> , 2021 , 96, E399-E402	7.1	3
63	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020 , 136, 7-8	2.2	2
62	Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2020 , 136, 29-30	2.2	2
61	Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.. <i>Journal of Hematology and Oncology</i> , 2022 , 15, 36	22.4	2
60	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2020 , 95, 1170	7.1	1
59	Glancing at the complex biology of T-cells through the microenvironment of Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1019-1021	1.9	1
58	Mass Cytometry Identifies Immunomic Shifts in the Bone Marrow Microenvironment of Multiple Myeloma and Light Chain Amyloidosis after Standard of Care First Line Therapies. <i>Blood</i> , 2018 , 132, 1879-1879 ¹	2.2	1
57	Changes in Imaging Surveillance of Diffuse Large B-Cell Lymphoma Survivors after Publication of the American Society of Hematology Choosing Wisely [®] Recommendations. <i>Blood</i> , 2018 , 132, 618-618	2.2	1
56	Multiparametric Analysis of Intra-Tumoral T-Cells in Hodgkin's Lymphoma Using Mass Cytometry (CyTOF). <i>Blood</i> , 2015 , 126, 1438-1438	2.2	1
55	Polatuzumab Vedotin Use before Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Aggressive Lymphoma: A US Single Center Experience. <i>Blood</i> , 2021 , 138, 3842-3842	2.2	1
54	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , 2021 , 138, 2527-2527	2.2	1
53	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018 , 132, 2884-2884	2.2	1
52	Initial presentation of CNS-restricted acute lymphoblastic B cell leukaemia as peripheral polyneuropathy. <i>BMJ Case Reports</i> , 2016 , 2016, 10.1136/bcr-2016-214645	0.9	1
51	Predictors of short-term survival in Waldenstrom's Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2975-2979	1.9	1

50	Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure. <i>Blood Cancer Journal</i> , 2021 , 11, 65	7	1
49	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. <i>Blood Cancer Journal</i> , 2021 , 11, 133	7	1
48	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. <i>Hematological Oncology</i> , 2021 , 39, 658-663	1.3	1
47	Uncovering Pharmacological Opportunities for Cancer Stem Cells-A Systems Biology View.. <i>Frontiers in Cell and Developmental Biology</i> , 2022 , 10, 752326	5.7	1
46	Peak Absolute Lymphocyte Count After CAR-T Infusion Predicts Clinical Response in Aggressive Lymphoma.. <i>American Journal of Hematology</i> , 2022 ,	7.1	1
45	Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndrome. <i>British Journal of Haematology</i> , 2020 , 190, 79-83	4.5	0
44	Response to Bridging Therapy (BT) before CAR-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2020 , 136, 30-30	2.2	0
43	Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience.. <i>Leukemia and Lymphoma</i> , 2022 , 1-6	1.9	0
42	Peak Absolute Lymphocyte Count Post CAR-T Is Associated with Clinical Response and Survival Outcome in Aggressive Lymphoma. <i>Blood</i> , 2021 , 138, 3856-3856	2.2	0
41	Central Nervous System Involvement By Mantle Cell Lymphoma. <i>Blood</i> , 2021 , 138, 2426-2426	2.2	0
40	Improvement in Outcomes of Autologous Stem Cell Transplant in Patients with Lymphoma Older Than 70 Years: The Significance of Age in 2020s?. <i>Blood</i> , 2021 , 138, 2908-2908	2.2	0
39	Immunologic Autograft Engineering: 13 Years Follow-up. <i>Blood</i> , 2021 , 138, 3936-3936	2.2	0
38	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. <i>Blood</i> , 2021 , 138, 568-568	2.2	0
37	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e19547-e19547	2.2	0
36	Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7554-7554	2.2	0
35	Characteristics, outcomes, and risk factors of ICANS after axicabtagene ciloleucel: Does age matter?. <i>Journal of Clinical Oncology</i> , 2021 , 39, e19556-e19556	2.2	0
34	Outcomes in mantle cell lymphoma with central nervous system involvement.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e19527-e19527	2.2	0
33	The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. <i>Blood Cancer Journal</i> , 2021 , 11, 124	7	0

32	Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel. <i>American Journal of Hematology</i> , 2021 , 96, E427-E430 ^O	7.1
31	Therapeutic targets and investigated strategies for treating B-cell non-Hodgkin lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 921-932	1.1
30	Changes in Frequency of Surveillance Imaging of Survivors of Diffuse Large B-Cell Lymphoma After the American Society of Hematology Choosing Wisely Recommendations. <i>JCO Oncology Practice</i> , 2021 , 17, e490-e496	2.3
29	High-Dimensional and Single-Cell Transcriptome Analysis of AITL Tumor Microenvironment Reveals Gross Expansion of Novel Dysfunctional CD8+ T Cell Populations, Global Shift in B Cell Phenotypes. <i>Blood</i> , 2020 , 136, 42-43	2.2
28	The Utility of Granulocyte Colony Stimulating Factor in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy with Axicabtagene Ciloleucel. <i>Blood</i> , 2020 , 136, 23-25	2.2
27	Hypomagnesemia Is Associated with an Increased Risk of Failure in Patients Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 21-21	2.2
26	Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2020 , 136, 42-43	2.2
25	Infused Autograft-Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B-Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched-Control Study. <i>Blood</i> , 2020 , 136, 8-9	2.2
24	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2020 , 136, 36-37.2	2.2
23	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. <i>Blood</i> , 2020 , 136, 17-18	2.2
22	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNENIS). <i>Blood</i> , 2021 , 138, 1333-1333	2.2
21	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1750-1750	2.2
20	Metabolic PET/CT Analysis of Aggressive Non-Hodgkin Lymphoma Prior to Axicabtagene Ciloleucel CAR-T Infusion: Predictors of Progressive Disease, Survival, and Toxicity. <i>Blood</i> , 2021 , 138, 2518-2518	2.2
19	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. <i>Blood</i> , 2021 , 138, 1373-1373	2.2
18	Response to Bridging Therapy As a Predictor of Outcomes for Chimeric Antigen Receptor Therapy in Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 3841-3841	2.2
17	Vaccine Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy. <i>Blood</i> , 2021 , 138, 3857-3857	2.2
16	Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 1439-1439	2.2
15	Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). <i>Blood</i> , 2018 , 132, 4138-4138	2.2

14	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2018 , 132, 4344-4344	2.2
13	Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 1517-1517	2.2
12	Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma. <i>Blood</i> , 2019 , 134, 2790-2790	2.2
11	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 5293-5293	2.2
10	Signal-Regulatory Protein-1 (SIRP-1) Expression Delineates Distinct Subsets in Monocytes/Macrophages in Normal Tissue and in B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 2515-2515	2.2
9	Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. <i>European Journal of Haematology</i> , 2021 , 107, 48-53	3.8
8	Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e19501-e19501	2.2
7	Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7558-7558	2.2
6	Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7542-7542	2.2
5	Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7530-7530	2.2
4	Vaccine titers in lymphoma patients receiving chimeric antigen receptor T-cell therapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7555-7555	2.2
3	Insurance status and survival in diffuse large B-cell lymphoma: A National Cancer Database study before and after the Affordable Care Act.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6539-6539	2.2
2	The impact of body weight and body mass index on outcomes of diffuse large B-cell lymphoma treated with axicabtagene ciloleucel.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e19554-e19554	2.2
1	Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.. <i>Leukemia and Lymphoma</i> , 2022 , 1-8	1.9